Andri Färber, Christiane Schwabe, Philipp H Stalder, Mateusz Dolata, Gerhard Schwabe
Physicians' and Patients' Expectations From Digital Agents for Consultations: Interview Study Among Physicians and Patients
JMIR human factors
artemetherlumefantrine widely used uncomplicated plasmodium falciparum malaria sulfadoxinepyrimethamine plus amodiaquine used seasonal malaria chemoprevention aimed determine efficacy artemetherlumefantrine without primaquine sulfadoxinepyrimethamine plus amodiaquine without tafenoquine reducing gametocyte carriage transmission mosquitoes phase 2 singleblind randomised clinical trial conducted ouelessebougou mali asymptomatic individuals aged 1050 years p falciparum gametocytaemia recruited community randomly assigned 1111 receive either artemetherlumefantrine artemetherlumefantrine single dose 025 mgkg primaquine sulfadoxinepyrimethamine plus amodiaquine sulfadoxinepyrimethamine plus amodiaquine single dose 166 mgkg tafenoquine trial staff pharmacist masked group allocation participants masked group allocation randomisation done computergenerated randomisation list concealed sealed opaque envelopes primary outcome median withinperson percent change mosquito infection rate infectious individuals baseline day 2 artemetherlumefantrine groups day 7 sulfadoxinepyrimethamine plus amodiaquine groups treatment assessed direct membrane feeding assay participants received trial drug included safety analysis study registered clinicaltrialsgov nct05081089 oct 13 dec 16 2021 1290 individuals screened 80 enrolled randomly assigned one four treatment groups 20 per group median age participants 13 iqr 1120 37 46 80 participants female 43 54 male individuals infectious treatment median percentage reduction mosquito infection rate 2 days treatment 1000 iqr 10001000 n19 p00011 artemetherlumefantrine 1000 10001000 n19 p00001 artemetherlumefantrine primaquine two individuals infectious baseline infected mosquitoes day 2 artemetherlumefantrine none day 5 contrast median percentage reduction mosquito infection rate 7 days treatment 636 iqr 001000 n20 p0013 sulfadoxinepyrimethamine plus amodiaquine 100 10001000 n19 p00001 sulfadoxinepyrimethamine plus amodiaquine tafenoquine grade 34 serious adverse events occurred data support effectiveness artemetherlumefantrine alone preventing nearly mosquito infections contrast considerable posttreatment transmission sulfadoxinepyrimethamine plus amodiaquine therefore addition transmissionblocking drug might beneficial maximising community impact bill melinda gates foundation